TY  - CHAP
M1  - Book, Section
TI  - Carbamazepine
A1  - COHEN, HENRY
A2  - Cohen, Henry
Y1  - 2015
N1  - 
T2  - Casebook in Clinical Pharmacokinetics and Drug Dosing
AB  - Carbamazepine  was  first  indicated  and  marketed  for  trigeminal  neuralgia  and  was  later  found  to  be  an  effective  antiepileptic.1  Carbamazepine  is  a  broad-spectrum  antiepileptic  drug  (AED)  and  is  indicated  for  partial  seizures  with  complex  symptomatology  (psychomotor,  temporal  lobe),  generalized  tonic-clonic  seizures  (grand  mal),  and  mixed  seizure  patterns.2,3  Extended-release  carbamazepine  is  also  indicated  alone  or  in  combination  with  other  antipsychotic  agents  for  acute  manic  or  mixed  episodes  associated  with  bipolar  1  disorder  either  as  treatment  or  prevention.4  Carbamazepine  may  be  used  as  an  adjunct  for  the  symptomatic  management  of  the  acute  phase  of  schizophrenia  in  patients  who  are  refractory  to  antipsychotics.4  Carbamazepine  has  also  been  used  for  the  management  of  restless  leg  syndrome,  peripheral  neuropathy,  diabetic  peripheral  neuropathy,  and  posttraumatic  stress  disorders.3,4  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1112257014
ER  -